Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNQ7TM)

Drug Name
Purvalanol A Drug Info
Synonyms
Purvalanola; AC1L1JD0; PURVALANOLA; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
Cross-matching ID
PubChem CID
456214
ChEBI ID
CHEMBL23327
CAS Number
CAS 212844-53-6
TTD Drug ID
D07OAT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Graft-versus-host disease 2.02 0.00e+0 32/42 (76.19%) HLA-B;HLA-F;HLA-DQA1;...
Rheumatoid arthritis 2.01 0.00e+0 78/93 (83.87%) CXCL2;CCL5;HLA-DQA1;...
Type I diabetes mellitus 1.98 0.00e+0 38/43 (88.37%) HLA-B;HLA-F;HLA-DQA1;...
Herpes simplex virus 1 infection 1.97 0.00e+0 165/498 (33.13%) SRC;CD74;HLA-B;...
Mineral absorption 1.97 0.00e+0 48/60 (80%) MT1E;MT1F;CYBRD1;...
Starch and sucrose metabolism 1.94 2.30e-3 25/36 (69.44%) SI;ENPP1;PGM1;...
Protein digestion and absorption 1.89 9.84e-3 78/103 (75.73%) COL15A1;CPB1;COL3A1;...
Proteoglycans in cancer 1.84 2.07e-2 172/205 (83.9%) CDKN1A;SRC;SDC4;...
TNF signaling pathway 1.83 1.84e-2 103/112 (91.96%) CXCL2;CASP7;JAG1;...
Sphingolipid metabolism 1.82 1.79e-2 32/49 (65.31%) PLPP3;GALC;PLPP2;...
Viral protein interaction with cytokine and cytokine re... 1.82 1.63e-2 84/100 (84%) CXCL2;CCL5;TNFSF10;...
Inflammatory mediator regulation of TRP channels 1.80 1.95e-2 82/98 (83.67%) PLA2G4A;SRC;GNAS;...
Allograft rejection 1.80 1.80e-2 32/38 (84.21%) HLA-B;HLA-F;HLA-DQA1;...
Gap junction 1.79 1.87e-2 72/88 (81.82%) SRC;GJA1;GNAS;...
Platelet activation 1.77 1.93e-2 106/124 (85.48%) PLA2G4A;SRC;GNAS;...
Amoebiasis 1.76 2.67e-2 99/102 (97.06%) CXCL2;GNAS;COL3A1;...
Phagosome 1.76 2.59e-2 118/152 (77.63%) HLA-B;CD36;HLA-F;...
Human cytomegalovirus infection 1.74 2.60e-2 201/225 (89.33%) CDKN1A;SRC;HLA-B;...
Viral myocarditis 1.74 2.61e-2 53/60 (88.33%) HLA-B;HLA-F;HLA-DQA1;...
Parathyroid hormone synthesis, secretion and action 1.73 2.69e-2 98/106 (92.45%) CDKN1A;GNAS;FGFR1;...
Dilated cardiomyopathy 1.73 2.62e-2 86/96 (89.58%) GNAS;DES;IGF1;...
Lysosome 1.73 2.63e-2 115/128 (89.84%) LAPTM4A;GALC;TPP1;...
Ether lipid metabolism 1.69 3.65e-2 32/49 (65.31%) PLA2G4A;PLPP3;ENPP2;...
Kaposi sarcoma-associated herpesvirus infection 1.69 3.62e-2 172/193 (89.12%) CDKN1A;SRC;CXCL2;...
Antigen processing and presentation 1.68 3.55e-2 60/78 (76.92%) CD74;HLA-B;HLA-F;...
Viral carcinogenesis 1.66 3.62e-2 149/203 (73.4%) CDKN1A;SRC;HLA-B;...
Rap1 signaling pathway 1.66 3.61e-2 184/210 (87.62%) ID1;SRC;GNAS;...
Relaxin signaling pathway 1.65 3.67e-2 114/129 (88.37%) SRC;GNAS;COL3A1;...
Focal adhesion 1.65 3.69e-2 180/201 (89.55%) SRC;THBS1;BIRC3;...
Cytokine-cytokine receptor interaction 1.64 3.62e-2 246/295 (83.39%) GDF15;CXCL2;IL17RB;...
DNA replication -1.64 4.08e-2 34/36 (94.44%) PCNA;POLA1;POLD2;...
RNA transport -1.64 4.53e-2 128/186 (68.82%) EIF3I;SENP2;EIF3B;...
Terpenoid backbone biosynthesis -1.67 4.04e-2 18/22 (81.82%) ACAT1;PMVK;IDI1;...
Basal transcription factors -1.69 3.93e-2 37/45 (82.22%) TAF5L;TBP;TAF4B;...
Cell cycle -1.82 1.06e-2 110/124 (88.71%) GADD45B;SMAD2;CDC14B;...
Aminoacyl-tRNA biosynthesis -1.83 1.16e-2 15/66 (22.73%) FARSA;LARS2;DARS2;...
Spliceosome -1.87 3.97e-3 101/150 (67.33%) DHX15;LSM8;SF3A3;...
Ribosome -1.91 5.30e-3 113/158 (71.52%) MRPL18;RPL14;RPS9;...
Steroid biosynthesis -1.92 7.94e-3 19/20 (95%) DHCR7;LBR;HSD17B7;...
Ribosome biogenesis in eukaryotes -2.05 0.00e+0 52/108 (48.15%) RPP30;POP4;SNU13;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H